Navigation Links
Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
Date:12/10/2008

p>

Some people taking paliperidone may feel faint or lightheaded when they stand up or sit up too quickly. By standing up or sitting up slowly and following your healthcare professional's dosing instructions, this side effect may be reduced or it may go away over time.

Paliperidone may affect your driving ability; therefore, do not drive or operate machinery before talking to your healthcare professional. Avoid alcohol while on paliperidone.

Paliperidone should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures.

Extrapyramidal Symptoms (EPS) are usually persistent movement disorders or muscle disturbances, such as restlessness, tremors, and muscle stiffness. If you observe any of these symptoms, talk to your healthcare professional.

Inform your healthcare professional if you are pregnant or if you are planning to get pregnant while taking paliperidone. Caution should be exercised when paliperidone is administered to a nursing woman.

Paliperidone may affect alertness and motor skills; use caution until the effect of paliperidone is known.

Paliperidone may make you more sensitive to heat. You may have trouble cooling off, or be more likely to become dehydrated, so take care when exercising or when doing things that make you warm.

Paliperidone should be swallowed whole. Tablets should not be chewed, divided, or crushed. Do not be worried if you see something that looks like a tablet in your stool. This is what is left of the tablet after all the medicine has been released.

The most common side effects that occurred with paliperidone were restlessness and extrapyramidal disorder (for example, involuntary movements, tremors and muscle stiffness). 


    References

    (a) Palipe
'/>"/>
SOURCE  Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 

Related biology technology :

1. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
6. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
7. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
8. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
9. SemBioSys begins phase I/II trial of insulin produced in plant seeds
10. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
11. OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/12/2010)... is taking strides to expand their Product and Material Testing Division ... ... Minneapolis, MN (PRWEB) March 12, 2010 -- DDL , leader ... to expand their Product and Material Testing Division by promoting Mark ... medical device manufacturers get to market for almost 20 years. ...
(Date:3/11/2010)... Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone ... ... , ... ... ...
(Date:3/11/2010)... has signed a definitive agreement with Elan Pharmaceuticals, Inc. (a subsidiary of Elan Corporation, plc) ( ELN) ("Elan") to acquire the analgesic therapy, PRIALT(R) (ziconotide ... ... ... ... ...
(Date:3/11/2010)... a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered ... for Sick Children (SickKids) in Toronto, Ontario , granting Trillium exclusive worldwide ... transplantation and cancer. , ... ... , ...
Breaking Biology Technology:DDL Expands the Product & Material Testing Division 2DDL Expands the Product & Material Testing Division 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 4FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 5FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 6FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 7FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 8Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 2Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 3Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 4Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 5Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 6Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 2Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 3
... 7, 2008 Light Sciences Oncology,Inc. (LSO) today announced ... Directors. The appointment increases Board membership to eight., ... a Director,of Endo Pharmaceuticals. He is the former President ... of Corporate Development with,Johnson & Johnson (NYSE: JNJ ...
... payments for achieving milestones ... ... TSX symbol: SBS, CALGARY, April 7 /PRNewswire-FirstCall/ - SemBioSys Genetics ... and cardiovascular diseases, today announced that it,has received milestone payments totaling ...
... Dr. David S. Young awarded "Most Innovative" award by the ... ... - ARIUS Research Inc. (TSX:,ARI), a biotechnology company discovering and ... David S. Young, President,and Chief Executive Officer, received the "Most ...
Other Biology Technology:Light Sciences Oncology Appoints David P. Holveck to Its Board of Directors 2SemBioSys receives milestone payments from AVAC Ltd. 2SemBioSys receives milestone payments from AVAC Ltd. 3SemBioSys receives milestone payments from AVAC Ltd. 4ARIUS recognized for entrepreneurial excellence 2
(Date:3/12/2010)... algae to produce hydrocarbon oil for biofuel production is ... of millions of years, according a Texas AgriLife Research ... braunii can be readily detected in petroleum deposits ... has been a contributor to developing these deposits and ... AgriLife Research scientist with the Texas A&M University department ...
(Date:3/12/2010)... Clemson University assistant professor of engineering and science ... Science Foundation Faculty Early Career Development (CAREER) Award ... decisions to enter engineering fields. , Trenor will ... of social capital to better understand undergraduate engineering ... Social capital is defined as resources gained from ...
(Date:3/12/2010)... of soil and irrigation is a vital factor in ... balance of the vineyard on wine quality and the ... order to innovate in this area, the NEIKER-Tecnalia technological ... temporary cover crop and different irrigation regimes for the ... on yield, vine vigour and grape and wine quality. ...
Breaking Biology News(10 mins):AgriLife scientists do groundwork for genetic mapping of algae biofuel species 2AgriLife scientists do groundwork for genetic mapping of algae biofuel species 3Clemson researcher receives grant to study engineering enrollment of women, minorities 2The use of cover crops in vineyards can help control the yield and quality of grapes and wine 2The use of cover crops in vineyards can help control the yield and quality of grapes and wine 3Cantel Medical Reports 65 25 Increase In Net Income EPS of 240 26 vs 240 16 For Quarter Ended July 31 2009 59196 1Cantel Medical Reports 65 25 Increase In Net Income EPS of 240 26 vs 240 16 For Quarter Ended July 31 2009 59196 2Cantel Medical Reports 65 25 Increase In Net Income EPS of 240 26 vs 240 16 For Quarter Ended July 31 2009 59196 3Cantel Medical Reports 65 25 Increase In Net Income EPS of 240 26 vs 240 16 For Quarter Ended July 31 2009 59196 4Cantel Medical Reports 65 25 Increase In Net Income EPS of 240 26 vs 240 16 For Quarter Ended July 31 2009 59196 5Cantel Medical Reports 65 25 Increase In Net Income EPS of 240 26 vs 240 16 For Quarter Ended July 31 2009 59196 6Cantel Medical Reports 65 25 Increase In Net Income EPS of 240 26 vs 240 16 For Quarter Ended July 31 2009 59196 7Soligenix Appoints Robert J Rubin MD to its Board of Directors 14405 1Soligenix Appoints Robert J Rubin MD to its Board of Directors 14405 2Soligenix Appoints Robert J Rubin MD to its Board of Directors 14405 3Soligenix Appoints Robert J Rubin MD to its Board of Directors 14405 4Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results 5361 1Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results 5361 2
... One of the simplest plants on the planet could help ... The moss Physcomitrella patens is a primitive plant, similar to ... 450 million years ago. Just one cell thick, these early ... without roots or complex leaves. The ability of mosses to ...
... a paper today that is the most comprehensive review ... having on the worlds coral reefs. The Carbon ... Ocean Acidification, co-authored by seventeen marine scientists from seven ... survive the drastic increases in global temperatures and atmospheric ...
... funded by the Lupus Research Institute (LRI) has discovered ... the inflammatory response of the immune system. The major ... journal Cell, means that new methods can now be ... regulation, and treat chronic autoimmune disorders such as lupus. ...
Other Biology News:Moss is a super model for feeding the hungry 2Immediate action needed to save corals from climate change 2Immediate action needed to save corals from climate change 3Profound immune system discovery opens door to halting destruction of lupus 2Profound immune system discovery opens door to halting destruction of lupus 3